On Wednesday, Cadence Design Systems Inc (NASDAQ:CDNS)’s shares inclined 0.81% to $20.02.
Cadence Design Systems Inc (CDNS) declared the next-generation Cadence® JasperGold® formal verification platform. This new formal verification solution integrates Cadence Incisive® formal technology and JasperGold technology into a single platform that delivers up to 15X performance improvement as compared to previous solutions. Moreover, as an integrated part of the Cadence System Development Suite, the JasperGold technology can assist to reduce verification plan by up to three months.
The JasperGold platform significantly improves design quality and efficiency by integrating a comprehensive set of features into one solution, counting:
- Design compilation and formal engine technologies from Incisive®Formal Verifier and Incisive Enterprise Verifier, counting the innovative Trident multi-cooperating engines. This enables easy migration for existing Incisive customers and up to 15X performance improvement for both bug-hunting and proof convergence modes.
- The next-generation JasperGold platform has been fully integrated with the Cadence System Development Suite’s Incisive simulation and Palladium®emulation platforms, and with vManager™ tool to enable comprehensive metric-driven verification. This results in an up to three-month plan reduction through formal-assisted verification closure.
- Proven JasperGold Visualize™ and QuietTrace™ technologies, which have been integrated with the Indago™ debug platform to further expand analysis and on-the-fly what-if exploration, assisting reduce root-cause debug time up to 5-100X.
Cadence Design Systems, Inc. develops, sells, leases, and licenses electronic design automation (EDA) software, emulation and prototyping hardware, verification intellectual property (VIP), and design intellectual property (design IP) for semiconductor and electronics systems industries worldwide. It offers functional verification products, including logic verification software that enables customers to coordinate verification activities across multiple teams and various specialists for verification planning and closure; and system design and verification products for hardware-software verification, as well as for system power exploration, analysis, and optimization.
Whole Foods Market, Inc. (NASDAQ:WFM)’s shares dropped -0.23% to $40.88.
Whole Foods Market, Inc. (WFM) is now the first major national grocery retailer in America to use the new, natural and sustainable choice in receipt paper that shoppers can feel good about at checkout.
A naturally occurring yellow tint assists Alpha Free stand out in a crowd and lets shoppers know what is (and isn’t!) in their receipt.
In addition to its unique formulation and yellow color, Alpha Free receipts are:
- 100 percent recyclable
- Compostable in most areas
- Made in the United States
With more shoppers than ever focused on green living and healthy options, switching to vitamin C-formulated Alpha Free receipts was an easy decision for Whole Foods.
Whole Foods Market is the first major grocery store chain to offer receipt paper free of controversial chemicals in both their Rocky Mountain and Southern California regions. Appvion’s partnership with Whole Foods Market supports Whole Foods Market’s dedication to providing naturally occurring and sustainable products as they start to cut down on waste while raising standards for employee and customer health.
Whole Foods Market, Inc. operates as a retailer of natural and organic foods. The company’s stores offer produce and floral, grocery, meat, seafood, bakery, prepared foods and catering, coffee, tea, beer, wine, cheese, nutritional supplements, vitamins, and body care products, in addition to lifestyle products, counting books, pet products, and household products. As of May 7, 2015, the company had about 417 stores worldwide.
At the end of Wednesday’s trade, Arrowhead Research Corp (NASDAQ:ARWR)‘s shares surged 7.62% to $7.20.
Arrowhead Research Corp (ARWR) declared that its Clinical Trial Application for ARC-520, its clinical candidate for chronic hepatitis B infection (HBV), has been approved by Germany’s Federal Institute for Drugs and Medical Devices. The company now has regulatory clearance in Germany for two additional Phase 2b multiple-dose studies of ARC-520 to be conducted in parallel. Arrowhead awaits final IRB approval from the sites, which are predictable shortly, and in addition, the company is engaged with regulatory authorities from Hong Kong and South Korea to open additional sites for these studies. Arrowhead will provide guidance in the future on timing for release of data from these studies.
The studies titled Heparc-2002 and Heparc-2003 will enroll patients with chronic HBV infection that are e-antigen (HBeAg) negative and HBeAg positive, respectively. Each study is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study intended to evaluate two dose levels in parallel of ARC-520 in combination with entecavir or tenofovir in patients with immune active chronic HBV infection. The 2002 and 2003 studies are planned to enroll up to 60 and 90 patients, respectively. In each study, patients will be randomized to receive four doses, once every 4 weeks, of either 1 mg/kg ARC-520, 2 mg/kg ARC-520, or placebo at a ratio of 1:1:1.
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology comprise Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types. The company is also involved in the development of Adipotide, which is in phase I clinical trial for the treatment of obesity and metabolic disorders; and CRLX-101 that is in phase II clinical trial to treat various cancer types, counting relapsed renal cell carcinoma, relapsed ovarian cancer, and non-metastatic rectal cancer.
Range Resources Corp. (NYSE:RRC), ended its Wednesday’s trading session with -2.15% loss, and closed at $52.74.
Range Resources Corp. (RRC) declared that its Board of Directors declared a quarterly cash dividend on its common stock for the second quarter. A dividend of $0.04 per common share is payable on June 30, 2015 to stockholders of record at the close of business on June 16, 2015.
Range Resources Corporation, an independent natural gas, natural gas liquids (NGLs), and oil company, engages in the acquisition, exploration, and development of natural gas and oil properties in the United States. It holds interests in developed and undeveloped natural gas and oil leases in the Appalachian and Midcontinent regions. The company owns 7,582 net producing wells and about 1.4 million net acres under lease in the Appalachian region; and 653 net producing wells and about 383,000 net acres under lease in the Midcontinent region.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
